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May 12th marked the 90th birthday of the medical pharmacologist Kurt Hellmann-one of the most eminent pioneers in metastasis research-whose foresight in science and medicine is unparalleled.
Inspired research and a close eye for detail led Kurt to the discovery of the unique cytostatic, cytoprotective and antimetastatic biological activities of bisdioxopiperazines in his laboratory at the ICRF Cancer Chemotherapy Unit Lincoln's Inn Fields, London, in the early 1970s. He resurrected the EDTA-analogues synthesised by Andrew Creighton but they had been patented by Geigy AG (now Novartis). Their characteristics and chemistry are excellently described by Marie Bakowski in Cancer Treatment Reviews 3, 95-107, 1976 .
The selective antimetastatic property of razoxane [ICRF 159] was first observed in the Lewis lung carcinoma (3LL) model utilized by Kurt as a screening system for studying compounds with potential inhibitory activity on metastasis. This work was regarded as a major breakthrough when published with Karen Burrage in Nature on 18 October 1969. A follow-up study by Kurt and his co-worker A.W. LeServe was published in the British Medical Journal in early 1972 ('Metastases and the normalization of tumour blood vessels by ICRF159: a new type of drug action') and reprinted as a 'classic' paper with an accompanying Editorial in Clinical & Experimental Metastasis in 2008. This important paper clearly showed for the first time that it was possible to 'normalize' tumour-induced pathologic vasculature by the prevention of intra-tumoral haemorrhage and hence the spread of cancer cells and subsequent lethal metastasis. This observation pre-dates by decades the recent popularisation of the idea that reversion of tumour vasculature to a more normal morphology could provide a valid therapeutic approach.
In the clinical context, the orally active razoxane analogue was subsequently shown by the British surgeon Jonathan Gilbert to prevent liver metastases in the adjuvant treatment of colorectal cancer. More recently it has been demonstrated by the Austrian radiotherapist Walter Rhomberg to potentiate certain schedules of chemoradiotherapy and to suppress metastasis in soft tissue sarcomas, in part by improvement of oxygen and drug delivery.
In the early 1970s, Kurt Hellmann brought razoxane to the attention of Abraham Goldin and Eugene Herman in the Laboratory of Chemical Pharmacology at the Clinical Center of the National Cancer Institute, Bethesda, MD. Herman found this intracellular active chelator to be highly effective in reducing anthracycline-induced cardiotoxicity in all species tested. This led to rapid NCI-supported clinical development of the parenteral, highly water soluble pure enantiomer (?) dexrazoxane [ICRF 187] by James Speyer (published in 1988/92) and definitively by Sandra Swain (published in 1997/98). These pivotal US prospective clinical studies clearly demonstrated effective, long-term cardioprotection by dexrazoxane, preserving the myocardial reserves in breast cancer patients but with no additional toxicities. These findings were subsequently confirmed in 2006 in a French registration trial led by Michel Marty. Currently, dexrazoxane is the only FDA/EMA approved agent for preventing anthracycline-induced cardiotoxicity which according to Ewer & Speyer 'must become an essential part of anthracycline-based modern chemotherapy practice' allowing for the optimization of such treatment modalities.
In the October 2010 issue of Lancet Oncology, the paediatric cardiologist Steven Lipshultz at the Department of Pediatrics, University of Miami Miller School of Medicine and the pediatric oncologist Stephen Sallan at Dana-Farber/ Children's Hospital Cancer Center, showed in a landmark prospective, randomised, multicentre trial of doxorubicintreated children with high-risk acute lymphoblastic leukaemia (ALL) that dexrazoxane provides cardioprotection without compromising oncological efficacy or enhancing the rate of second malignancies in the long-term follow-up. On April 1, 2012 a further report by the same group published in the Journal of Clinical Oncology underscored the importance of dexrazoxane administered before each dose of doxorubicin to reduce cardiotoxicity and urged the use of a comprehensive panel of biomarkers to assess cardiac status in the long-term follow-up of patients treated with the clinically proven, cost-effective anthracyclines.
This account cannot end without quoting verbatim from a letter of support from James Doroshow, Director, Division of Cancer Treatment and Diagnosis US National Cancer Institute, for a meeting organised by Kurt Hellmann on 'Cancer Therapy Improvement by Toxicity Reduction and Cardioprotection' at the Royal Society of Medicine, London, in October 2006. Doroshow wrote ''it is a great pleasure to extend to you and the extraordinary group of experts in the area of anthracycline clinical pharmacology that you have assembled, my very best wishes for what will be an important examination of the continuing role of dexrazoxane in the prevention of cardiac damage produced by the anthracycline antibiotics. The critical roles played by all of the speakers in the Symposium in developing our current understanding of the mechanism of anthracycline cardiac toxicity were essential in the approval of dexrazoxane by the US Food and Drug Administration. With a decade of clinical application in hand, it would seem that an expansion of the use of this important protective agent should be considered…''.
Further exploration of the drug's cytoprotective activity beyond the FDA/EMA approved treatment showed that the serious consequences of accidental anthracycline extravasation could also be ameliorated or prevented by dexrazoxane. This work was undertaken in 2007 because of the widespread chelation activity of the bisdioxopiperazines and the known inhibition of cell division at the G2/M transition. Additional considerations were the ability of both piperazines to block topoisomerase II alpha, cellular senescence, apoptosis and induction of thrombospondin-1. The neuroprotective dexrazoxane was found to enhance the efficacy of mitoxantrone in a rat model of multiple sclerosis by the German neurologist Franz Weilbach.
In addition, razoxane and dexrazoxane were recently shown to reduce beta amyloid peptide levels in preclinical studies of Alzheimer's disease by Nigel Greig at NIH, confirming Gerhard Zbinden's findings in 1983 that protection is possible in neuronal tissues. It is a testament to Kurt Hellmann's initiatives and foresight that both the Society and journal continue to thrive. The Metastasis Research Society has attracted over 300 members from 30 countries and its biennial international conferences (held in most major European countries, the USA and Japan) routinely attract 300-400 delegates from all over the world. The next conference will be held in Brisbane in September 2012, its first time in Australia. Clinical & Experimental Metastasis enjoys a reputation as a high profile specialist journal with an impact factor fast approaching 5.0; serving both research scientists and clinicans with interests in the basic biology, prevention and treatment of disseminated disease.
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